Unlike transactional, one-off appointments, Maven emphasizes a full story approach where care plans evolve alongside the user, ensuring that fertility questions, pregnancy planning, and hormone care are connected through a unified clinical history
The question is: will you adjust before your next buy cycle locks in outdated assumptions
[13] [14] UK SmPCs for licensed GLP-1 receptor agonists do not list medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) as formal contraindications, but advise vigilance for symptoms such as a neck lump, hoarseness, or difficulty swallowing
"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept." Cell Metabolism